C a Difference

VISUALIZING A FUTURE FREE OF HEPATITIS C

We have a new Patient Navigator!

Highlights

- Please welcome **Carla Coleman**, the new patient navigator for C a Difference.
- New treatment guidelines were released by AALSD. Patients with or without cirrhosis reach SVR in just 12 weeks at a rate of 99%.
- LabCorp has changed its reflex test for confirming active HCV. The HCV Antibody with Reflex to Quantitative Real-time PCR will be replaced by **HCV Antibody with Reflex to HCV RNA, Qualitative, NAA.**

Carla Coleman is the patient navigator for "C a Difference". Carla received her BSW from Temple in 2006 and her MBA with a concentration in Public Administration from Strayer in 2013. Carla has been working in public health for 13 years, her last position was at Delaware County Office of Services for the Aging (COSA) in the protective service unit.

Carla's number is **267-507-6599**. Please email **Carla.Coleman@drexelmed.edu** or task **Carla Coleman** to reach Carla about new positive patients or any other concerns.

IMPORTANT!

LabCorp has replaced the HCV Antibody with Reflex to Quantitative Real-time PCR (144028) to the HCV Antibody with Reflex to HCV RNA, Qualitative, NAA (144045). **If the prior test was ordered after 3/16, the results for the HCV test can be found under the new test name "HCV Antibody Reflex to NAA".**



The newest treatment guidelines released by AASLD have been released. For genotype 1, the most common in the US, **Harvoni** is recommended. Harvoni is a combination of Ledipasvir and Sofosbuvir given over the course of 12 weeks for treatment-naïve patients with or without cirrhosis.

We want to hear your feedback!

Let us know how we can help you improve testing practices: Lora.Magaldi@Drexelmed.edu